FibroGen Swings to Profit on China Divestiture, R&D Plummets

TL;DR

**FibroGen's China sale was a necessary cash grab, but the core business is still bleeding, making it a speculative bet on FG-3246.**

AI Summary

FIBROGEN INC (KYNB) reported a significant turnaround, posting a net income of $200.6 million for the three months ended September 30, 2025, compared to a net loss of $17.1 million in the same period of 2024. This dramatic shift was primarily driven by $213.8 million in income from discontinued operations, net of tax, largely due to the sale of its China operations to AstraZeneca Treasury Limited for $220.4 million on August 29, 2025. Total revenue from continuing operations, however, decreased to $1.1 million for the quarter, down from $123,000 in Q3 2024, and significantly lower than the $26.5 million reported in Q3 2024 before reclassification of discontinued operations. Research and development expenses for continuing operations plummeted to $1.2 million from $19.9 million year-over-year, reflecting a strategic shift post-divestiture. The company's cash and cash equivalents increased to $118.0 million as of September 30, 2025, from $50.5 million at December 31, 2024, bolstered by the divestiture proceeds. A loss on debt extinguishments of $6.6 million was recorded for the nine months ended September 30, 2025, related to the repayment of senior secured term loan facilities. The company also initiated a Phase 2 monotherapy dose optimization study for FG-3246 in mCRPC in Q3 2025 and received positive FDA feedback for roxadustat in lower-risk MDS.

Why It Matters

This filing signals a pivotal strategic shift for FibroGen, moving away from its China operations and significantly reducing its R&D spend on continuing operations. For investors, the $220.4 million divestiture provides a much-needed cash infusion, boosting liquidity to $118.0 million and reducing total liabilities from $398.2 million to $119.5 million. This could stabilize the company's financial position, but the sharp decline in continuing operations revenue to $1.1 million raises questions about future growth drivers outside of the FG-3246 program and the remaining roxadustat rights. Employees may face further restructuring as the company streamlines, while customers and the broader market will watch how FibroGen competes with its focused pipeline, particularly in the mCRPC and MDS spaces, against larger pharmaceutical players.

Risk Assessment

Risk Level: medium — While the company reported a net income of $200.6 million for Q3 2025, this was primarily due to a one-time gain from discontinued operations. Revenue from continuing operations was only $1.1 million for the quarter, indicating a very limited revenue stream post-divestiture. The company still operates with a total stockholders' deficit of $17.0 million, and its long-term viability hinges heavily on the success of its FG-3246 program and the remaining roxadustat indications, which are subject to significant clinical and regulatory risks.

Analyst Insight

Investors should view FibroGen as a high-risk, high-reward biotech play. The cash from the China divestiture provides a runway, but the core business is extremely lean. Consider a small, speculative position only if you have a high tolerance for risk and believe in the potential of FG-3246 and roxadustat in MDS, as future revenue generation is highly dependent on these pipeline assets.

Financial Highlights

debt To Equity

N/A

revenue

$1.1M

operating Margin

N/A

total Assets

$137.0M

total Debt

$119.5M

net Income

$200.6M

eps

N/A

gross Margin

N/A

cash Position

$118.0M

revenue Growth

-95.8%

Revenue Breakdown

Key Numbers

• $200.6M — Net income for Q3 2025 (Significant turnaround from a net loss of $17.1 million in Q3 2024, primarily due to discontinued operations.)
• $213.8M — Income from discontinued operations, net of tax, for Q3 2025 (Main driver of net income, stemming from the sale of China operations.)
• $220.4M — Total consideration from China operations sale (Comprised of $85.0 million enterprise value and $135.4 million net cash held in China.)
• $1.1M — Total revenue from continuing operations for Q3 2025 (Represents a very limited revenue stream post-divestiture, down from $26.5 million in Q3 2024 (before reclassification).)
• $1.2M — Research and development expenses for Q3 2025 (Dramatic decrease from $19.9 million in Q3 2024, reflecting strategic shift and divestiture.)
• $118.0M — Cash and cash equivalents as of September 30, 2025 (Increased from $50.5 million at December 31, 2024, due to divestiture proceeds.)
• $6.6M — Loss on debt extinguishments for nine months ended September 30, 2025 (Related to the repayment of senior secured term loan facilities.)
• $17.0M — Total stockholders' deficit attributable to FibroGen as of September 30, 2025 (Improved from $225.6 million at December 31, 2024, but still a deficit.)
• 4,045,445 — Common shares outstanding as of October 31, 2025 (Reflects the 1-for-25 reverse stock split effected on June 16, 2025.)
• $119.5M — Total liabilities as of September 30, 2025 (Significantly reduced from $398.2 million at December 31, 2024, post-divestiture.)

Key Players & Entities

• FIBROGEN INC (company) — registrant
• AstraZeneca Treasury Limited (company) — buyer of China operations
• AstraZeneca AB (company) — commercialization partner for roxadustat
• Astellas Pharma Inc. (company) — commercialization partner for roxadustat in Europe and Japan
• U.S. Food and Drug Administration (regulator) — regulatory body for drug approvals
• FG-3246 (product) — potential first-in-class antibody-drug conjugate
• roxadustat (product) — approved drug for anemia in CKD patients
• FibroGen International (Hong Kong) Ltd. (company) — divested China operations
• September 30, 2025 (date) — end of reporting period
• August 29, 2025 (date) — closing date of China operations sale

FAQ

Risk Factors

• Dependence on Divestitures for Profitability [high — financial]: The company's reported net income of $200.6 million in Q3 2025 is heavily reliant on a $213.8 million gain from discontinued operations (sale of China business). This indicates a lack of sustainable profitability from continuing operations, which generated only $1.1 million in revenue.
• Reduced R&D Investment [medium — operational]: Research and development expenses for continuing operations plummeted to $1.2 million in Q3 2025 from $19.9 million in Q3 2024. This drastic reduction signals a significant shift in strategic focus and may impact future product pipeline development.
• Substantial Stockholders' Deficit [medium — financial]: Despite improvements, the company still has a total stockholders' deficit of $17.0 million as of September 30, 2025. This, combined with a history of losses, suggests a fragile financial position that may require further restructuring or capital raises.
• Loss on Debt Extinguishment [low — financial]: A loss of $6.6 million was recorded for the nine months ended September 30, 2025, due to the repayment of senior secured term loan facilities. While debt reduction is positive, the associated loss highlights the costs of financial restructuring.
• Limited Revenue from Continuing Operations [high — market]: Total revenue from continuing operations was only $1.1 million in Q3 2025, a stark contrast to the $26.5 million reported in Q3 2024 (before reclassification). This highlights the challenge of generating meaningful revenue from the remaining business segments.
• FDA Feedback and Development Milestones [medium — regulatory]: While positive FDA feedback for roxadustat in lower-risk MDS is encouraging, the company's reliance on specific drug development programs (like FG-3246) carries inherent regulatory and clinical trial risks.

Industry Context

FibroGen operates in the highly competitive biopharmaceutical industry, focusing on developing treatments for serious unmet medical needs. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Recent trends include strategic divestitures to streamline operations and focus on core assets, as well as advancements in targeted therapies for conditions like cancer and blood disorders.

Regulatory Implications

The company faces ongoing regulatory scrutiny from bodies like the FDA, particularly concerning the development and approval of its drug candidates. Positive feedback for roxadustat is a good sign, but the success of FG-3246 and other pipeline assets hinges on successful clinical trials and regulatory navigation. The significant reduction in R&D spending could also impact the pace of future regulatory submissions.

What Investors Should Do

1. Monitor revenue generation from continuing operations.
2. Assess the long-term impact of reduced R&D spending.
3. Evaluate the sustainability of profitability.
4. Track cash burn and future financing needs.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported significant net income driven by divestiture, but low revenue from continuing operations.
• 2025-08-29: Sale of China operations to AstraZeneca — Generated $220.4 million in proceeds, significantly boosting cash and resulting in a large gain from discontinued operations.
• 2025-06-16: 1-for-25 reverse stock split — Reduced the number of outstanding common shares to 4,045,445 as of October 31, 2025, likely to meet exchange listing requirements or improve per-share metrics.

Glossary

Discontinued operations

A segment of a business that has been sold, abandoned, or is being disposed of. Its financial results are reported separately from continuing operations. (The sale of FibroGen's China operations as discontinued operations is the primary driver of the company's reported net income for the period.)

Stockholders' deficit

Occurs when a company's total liabilities exceed its total assets, resulting in a negative net worth for shareholders. (FibroGen still has a stockholders' deficit of $17.0 million, indicating a negative equity position despite recent improvements.)

Loss on debt extinguishment

A loss recognized when a company repays debt before its scheduled maturity date, often due to refinancing at a lower interest rate or restructuring. (FibroGen recorded a $6.6 million loss related to repaying its senior secured term loan facilities.)

mCRPC

Metastatic Castration-Resistant Prostate Cancer, an advanced stage of prostate cancer. (FibroGen is conducting a Phase 2 study for FG-3246 in this specific patient population.)

MDS

Myelodysplastic Syndromes, a group of blood cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells. (FibroGen received positive FDA feedback for roxadustat in lower-risk MDS.)

Reverse stock split

A corporate action to reduce the number of outstanding shares of a company's stock, typically to increase the share price. (FibroGen executed a 1-for-25 reverse stock split, significantly reducing its share count.)

Year-Over-Year Comparison

FibroGen has undergone a dramatic transformation, primarily driven by the sale of its China operations. This resulted in a significant swing from a net loss of $17.1 million in Q3 2024 to a net income of $200.6 million in Q3 2025, largely due to a $213.8 million gain from discontinued operations. Revenue from continuing operations has drastically fallen to $1.1 million from $26.5 million year-over-year, and R&D expenses have been slashed from $19.9 million to $1.2 million, indicating a substantial strategic pivot. Total liabilities have also decreased significantly from $398.2 million to $119.5 million, while cash reserves have more than doubled to $118.0 million, bolstered by the divestiture proceeds.

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se

Filing Documents

• fgen-20250930.htm (10-Q) — 3285KB
• fgen-ex10_1.htm (EX-10.1) — 57KB
• fgen-ex10_2.htm (EX-10.2) — 262KB
• fgen-ex10_3.htm (EX-10.3) — 80KB
• fgen-ex31_1.htm (EX-31.1) — 10KB
• fgen-ex31_2.htm (EX-31.2) — 10KB
• fgen-ex32_1.htm (EX-32.1) — 10KB
• 0001193125-25-274241.txt ( ) — 12401KB
• fgen-20250930.xsd (EX-101.SCH) — 1940KB
• fgen-20250930_htm.xml (XML) — 1879KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 2 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (Unaudited) 2 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Changes in Redeemable Non-controlling Interests and Stockholders' Deficit for the Three and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 7 Notes to the Condensed Consolidated Financial Statements (Unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 42

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 43 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 72 Item 3. Defaults Upon Senior Securities 72 Item 4. Mine Safety Disclosures 72 Item 5. Other Information 72 Item 6. Exhibits 72

Signatures

Signatures 74 1 Table of Contents FIBROGEN, INC.

—FINANCIA L INFORMATION

PART I—FINANCIA L INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS CONDENSED CONSOLIDA TED BALANCE SHEETS (In thousands, except per share amounts) (Unaudited) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 117,975 $ 50,482 Accounts receivable, net 121 481 Inventories 3,864 3,155 Prepaid expenses and other current assets 11,463 31,542 Current assets held for sale — 110,849 Total current assets 133,423 196,509 Long-term investments 3,035 — Other assets 556 1,405 Long-term assets held for sale — 16,611 Total assets $ 137,014 $ 214,525 Liabilities, redeemable non-controlling interests and deficit Current liabilities: Accounts payable $ 5,093 $ 5,064 Accrued and other current liabilities 25,776 62,035 Deferred revenue 5,104 27,290 Current liabilities held for sale — 38,917 Total current liabilities 35,973 133,306 Product development obligations 19,471 17,012 Deferred revenue, net of current 573 114,708 Senior secured term loan facilities, non-current — 73,092 Liability related to sale of future revenues, non-current 63,414 58,864 Other long-term liabilities 98 822 Long-term liabilities held for sale — 356 Total liabilities 119,529 398,160 Commitments and Contingencies (Note 11) Redeemable non-controlling interests 21,480 21,480 Stockholders' deficit: Preferred stock, $ 0.01 par value; 125,000 shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.01 par value; 225,000 shares authorized at September 30, 2025 and December 31, 2024; 4,045 and 4,037 shares issued and outstanding at September 30, 2025 and December 31, 2024 1,011 1,009 Additional paid-in capital 1,675,999 1,668,620 Accumulated other comprehensive loss ( 2,211 ) ( 5,732 ) Accumulated deficit ( 1,691,827 ) ( 1,889,499 ) Total stockholde

View Full Filing

View this 10-Q filing on SEC EDGAR